Table 3.

Summary of disease assessment criteria identified in proactive treatment regimen in randomised controlled trials of neovascular age-related macular degeneration

Study	Type of disease assessment criteria used to modify treatment interval
	OCT change in morphology: qualitative (e.g. increase in IRF)	New haemorrhage due to nAMD	Visual acuity reduction only	Increase in lesion size on FFA or other retinal imaging modality	OCT change in morphology with visual acuity reduction	OCT thickness increase only	Both visual acuity reduction and CST thickness increase
LUCAS (2015)	Yes	Yes	No	Yes	No	No	No
VIEW (2012)	No	Yes	Yes	Yes	Yes	Yes	No
TREX-AMD (2015)	Yes	Yes	No	No	No	No	No
FLUID (2016)	Yes	Yes	Yes	Yes	No	Yes	No
TREND (2017)	Yes	No	No	No	No	No	No
RIVAL (2019)	Yes	Yes	Yes	No	No	No	No
CANTREAT (2019)	Yes	Yes	Yes	Yes	No	No	No
ALTAIR (2020)	Yes	Yes	No	Yes	Yes	Yes	No
ARIES (2020)	Yes	Yes	No	Yes	No	Yes	No
HAWK & HARRIER (2019)	Yes	No	Yes	No	Yes	No	Yes
TENAYA & LUCERNE (2022)	No	Yes	No	No	Yes	Yes	No
TREX-Conbercept (2022)	Yes	Yes	Yes	No	No	No	No
Number of studies using this type of disease assessment criterion	10	10	6	6	4	5	1

CST central subfield thickness, FFA fundus fluorescein angiogram, IRF intraretinal fluid, nAMD neovascular age-related macular degeneration, OCT optical coherence tomography